NasdaqGS - Delayed Quote • USD
Alkermes plc (ALKS)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 8 | 8 | 9 | 9 |
Avg. Estimate | 0.6 | 0.74 | 2.76 | 2.58 |
Low Estimate | 0.53 | 0.68 | 2.49 | 2.03 |
High Estimate | 0.68 | 0.8 | 2.9 | 3.16 |
Year Ago EPS | 0.01 | 0.55 | 1.44 | 2.76 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 10 | 9 | 12 | 12 |
Avg. Estimate | 362.62M | 389.74M | 1.52B | 1.52B |
Low Estimate | 347.93M | 379.17M | 1.46B | 1.43B |
High Estimate | 374.7M | 395.79M | 1.56B | 1.74B |
Year Ago Sales | 287.6M | 617.4M | 1.66B | 1.52B |
Sales Growth (year/est) | 26.10% | -36.90% | -8.70% | 0.40% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.01 | 0.46 | 0.44 | 0.51 |
EPS Actual | 0.01 | 0.55 | 0.64 | 0.22 |
Difference | 0.02 | 0.09 | 0.2 | -0.29 |
Surprise % | 200.00% | 19.60% | 45.50% | -56.90% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.6 | 0.74 | 2.76 | 2.58 |
7 Days Ago | 0.61 | 0.75 | 2.78 | 2.67 |
30 Days Ago | 0.69 | 0.79 | 2.73 | 2.7 |
60 Days Ago | 0.69 | 0.79 | 2.73 | 2.7 |
90 Days Ago | 0.49 | 0.56 | 2.29 | 2.51 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | 1 | 1 | 3 | 2 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 2 | 1 | 1 | 2 |
Growth Estimates
CURRENCY IN USD | ALKS | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 5,900.00% | -- | -- | 6.50% |
Next Qtr. | 34.50% | -- | -- | 12.00% |
Current Year | 91.70% | -- | -- | 5.30% |
Next Year | -6.50% | -- | -- | 13.10% |
Next 5 Years (per annum) | 24.80% | -- | -- | 11.09% |
Past 5 Years (per annum) | 3.24% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Neutral to Neutral | 4/19/2024 |
Maintains | Jefferies: Buy to Buy | 4/9/2024 |
Reiterates | Piper Sandler: Overweight to Overweight | 4/1/2024 |
Initiated | Baird: Outperform | 3/19/2024 |
Downgrade | UBS: Neutral to Sell | 2/20/2024 |
Maintains | Piper Sandler: Overweight to Overweight | 2/16/2024 |
Related Tickers
IRWD Ironwood Pharmaceuticals, Inc.
7.82
-3.22%
NBIX Neurocrine Biosciences, Inc.
135.99
-1.28%
DCPH Deciphera Pharmaceuticals, Inc.
14.65
+3.31%
EGRX Eagle Pharmaceuticals, Inc.
4.1600
-1.89%
ITCI Intra-Cellular Therapies, Inc.
73.26
+1.57%
LFCR Lifecore Biomedical, Inc.
6.60
-0.68%
ANIP ANI Pharmaceuticals, Inc.
65.36
+0.63%
INDV Indivior PLC
17.58
+1.91%
SUPN Supernus Pharmaceuticals, Inc.
30.07
+2.59%
COLL Collegium Pharmaceutical, Inc.
36.42
+1.62%